Cue Biopharma, Inc. (CUE) Spending and interest coverage
- R&D / revenue · 12 months: Value 204.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 69.12%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 204.99% | Research and development expense / revenue. Period ending 2026-06-30. $77.19M ÷ $37.66M × 100 ≈ 204.99% |
| Stock-based compensation / revenue · 12 months | 69.12% | Share-based compensation / revenue. Period ending 2026-06-30. $26.03M ÷ $37.66M × 100 ≈ 69.12% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 77.19M USD | Research and Development Expense |
| Revenue | 37.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 26.03M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -98.67M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $77.19M | $37.66M | $26.03M | $-98.67M | (m) | 204.99% | 69.12% | (m) | (m) |
| 2026-03-31 | $36.09M | $32.73M | $3.45M | $-19.61M | (m) | 110.27% | 10.55% | (m) | (m) |
| 2025-12-31 | $37.74M | $27.47M | $4.74M | $-26.55M | $100.00K | 137.42% | 17.27% | -265.52× | Reported |
| 2025-09-30 | $28.39M | $7.10M | $5.70M | $-38.16M | (m) | 399.93% | 80.23% | (m) | (m) |
| 2025-06-30 | $33.02M | $8.29M | $5.75M | $-39.38M | (m) | 398.54% | 69.35% | (m) | (m) |
| 2025-03-31 | $34.64M | $7.99M | $6.24M | $-41.13M | (m) | 433.53% | 78.06% | (m) | (m) |
| 2024-12-31 | $36.30M | $9.29M | $6.85M | $-41.50M | $100.00K | 390.82% | 73.72% | -415.00× | Reported |
| 2024-09-30 | $40.00M | $9.53M | $7.36M | $-45.70M | (m) | 419.62% | 77.17% | (m) | (m) |
| 2024-06-30 | $40.49M | $8.29M | $7.85M | $-48.30M | (m) | 488.13% | 94.59% | (m) | (m) |
| 2024-03-31 | $41.61M | $7.02M | $8.13M | $-51.44M | $130.00K | 592.74% | 115.78% | -395.67× | Reported |
| 2023-12-31 | $40.80M | $5.49M | $8.18M | $-52.15M | $130.00K | 743.21% | 149.00% | -401.15× | Reported |
| 2023-09-30 | $41.25M | $3.82M | $8.22M | $-53.18M | (m) | 1079.70% | 215.17% | (m) | (m) |
| 2023-06-30 | $38.94M | $1.79M | $8.21M | $-52.79M | (m) | 2176.59% | 458.91% | (m) | (m) |
| 2023-03-31 | $37.89M | $432.23K | $8.48M | $-52.37M | (m) | 8765.55% | 1962.60% | (m) | (m) |
| 2022-12-31 | $38.58M | $1.25M | $9.50M | $-53.22M | (m) | 3098.08% | 762.58% | (m) | (m) |
| 2022-09-30 | $38.75M | $9.35M | $10.36M | $-46.25M | (m) | 414.48% | 110.81% | (m) | (m) |
| 2022-06-30 | $42.44M | $11.68M | $11.55M | $-48.22M | (m) | 363.51% | 98.88% | (m) | (m) |
| 2022-03-31 | $41.61M | $14.39M | $12.09M | $-45.43M | (m) | 289.21% | 84.03% | (m) | (m) |
| 2021-12-31 | $41.35M | $14.94M | $11.52M | $-43.71M | (m) | 276.73% | 77.07% | (m) | (m) |
| 2021-09-30 | $37.85M | $7.16M | $10.82M | $-46.79M | (m) | 528.46% | 151.11% | (m) | (m) |
| 2021-06-30 | $34.10M | $5.47M | $10.07M | $-43.93M | (m) | 623.32% | 184.12% | (m) | (m) |
| 2021-03-31 | $33.46M | $3.81M | $9.74M | $-44.57M | (m) | 878.72% | 255.87% | (m) | (m) |
| 2020-12-31 | $33.55M | $3.15M | $10.48M | $-45.04M | (m) | 1063.48% | 332.27% | (m) | (m) |
| 2020-09-30 | $32.51M | $3.73M | $10.19M | $-43.08M | (m) | 871.88% | 273.45% | (m) | (m) |
| 2020-06-30 | $30.29M | $4.01M | $9.13M | $-40.05M | (m) | 755.74% | 227.90% | (m) | (m) |
| 2020-03-31 | $29.04M | $3.99M | $7.93M | $-38.34M | (m) | 728.14% | 198.78% | (m) | (m) |
| 2019-12-31 | $27.49M | $3.46M | $6.52M | $-36.77M | (m) | 794.82% | 188.56% | (m) | (m) |
| 2019-09-30 | $27.35M | $2.74M | $6.54M | $-38.72M | (m) | 998.18% | 238.56% | (m) | (m) |
| 2019-06-30 | $32.36M | $2.20M | $7.83M | $-44.38M | (m) | 1467.61% | 354.97% | (m) | (m) |
| 2019-03-31 | $31.08M | $1.32M | $7.78M | $-42.60M | (m) | 2351.54% | 588.96% | (m) | (m) |
| 2018-12-31 | $28.54M | $1.14M | $7.17M | $-38.70M | (m) | 2498.16% | 627.84% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $18.90M | (m) | $2.78M | $-23.23M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |